中等剂量卡培他滨单药治疗转移性乳腺癌的疗效及安全性

Efficacy and Safety of Moderate-dose Capecitabine in Treatment of Metastatic Breast Cancer

目的观察中等剂量[2 000mg/(m2.d)]卡培他滨治疗转移性乳腺癌的疗效和不良反应。方法卡培他滨单药治疗43例转移性乳腺癌,2 000mg/(m2.d),d1～14,每3周为1周期。结果 43例患者平均行8周期卡培他滨治疗,客观缓解率(CR+PR)为18.6%,临床获益率(CR+PR+SD)为86.0%。整体的中位无进展生存期(PFS)为7.1月(95%CI:5.8～8.4),在一线治疗、二线治疗和三线及以上治疗亚组中差异无统计学意义,分别为7.1月、6.1月和8.1月(P=0.390)。在蒽环类药物与紫杉类药物治疗均失败的患者中,PFS明显缩短(6.1月vs.7.1月,P=0.038)。大于65岁的患者PFS显著延长(8.1月vs.6.1月,P=0.045)。主要不良反应为手足综合征19例(44.2%)。结论中等剂量[2 000mg/(m2.d)]卡培他滨单药治疗转移性乳腺癌安全、有效。

Objective To determine activity and safety of capecitabine at a moderate dose of 2000mg/（m2.d）for metastatic breast cancer.Methods In this retrospective trial,43metastatic breast cancer patients received first-line capecitabine 2 000mg/m2 on days 1～14every 3weeks.Results 43metastatic breast cancer patients received mean 8cycles of capecitabine therapy.Median PFS was 7.1months（95% CI：5.8～8.4）.There were no difference among the first line,the second line and third line treatment 7.1 months,6.1months,and 8.1months respectively（P=0.390）.Patients pretreated with both anthracycline and taxane therapy had a significantly shorter PFS（6.1months vs.7.1months,P=0.038）,but patients〉65years achieved a significantly longer PFS（8.1months vs.6.1months,P=0.045）.Ninteen cases（44.2%）had hand-foot syndrome,a main toxicity.Conclusion Capecitabine at a moderate dose of 2 000mg/（m2.d）is active and well-tolerated for metastatic breast cancer.